However, despite the current surge in studies investigating the clinical impact of PSMA-PET for prostate cancer, to our knowledge, no prospective study has yet evaluated the radiation dosimetry of [68Ga]PSMA-11 in a cohort of low-risk prostate cancer patients. The gene discussed is FOLH1; the disease is prostate carcinoma.